<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; stakeholder</title>
	<atom:link href="http://www.tapanray.in/tag/stakeholder/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Ticking Some Right Boxes Biosimilar Drugs’ Acceptance Gaining Steam in India</title>
		<link>http://www.tapanray.in/ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india</link>
		<comments>http://www.tapanray.in/ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india/#comments</comments>
		<pubDate>Sun, 24 Sep 2023 06:26:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acceptance]]></category>
		<category><![CDATA[arbitrage]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Boxes]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[initiatives]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[ticking]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10828</guid>
		<description><![CDATA[Looking at a broader canvas, on September 19, 2023, a credible international report flashed a headline, ‘Biosimilars making inroads into Humira sales, but docs still cautious on switching: Spherix.’ This is based on a survey of U.S. healthcare specialists, including 80 dermatologists, &#8230; <a href="http://www.tapanray.in/ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Branding At Tough Times</title>
		<link>http://www.tapanray.in/pharma-branding-at-tough-times/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-branding-at-tough-times</link>
		<comments>http://www.tapanray.in/pharma-branding-at-tough-times/#comments</comments>
		<pubDate>Mon, 18 Nov 2019 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[failures]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Prompt]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[times]]></category>
		<category><![CDATA[Tough]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9784</guid>
		<description><![CDATA[“About two-thirds of drug launches don’t meet expectations. Improving that record requires pharmaceutical companies to recognize the world has changed and adjust their marketing accordingly.” This appeared in an article – “The secret of successful drug launches,” published by McKinsey &#38; Company in &#8230; <a href="http://www.tapanray.in/pharma-branding-at-tough-times/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-branding-at-tough-times/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma ‘Chatbots’: For Better Stakeholder Engagement</title>
		<link>http://www.tapanray.in/pharma-chatbots-for-better-stakeholder-engagement/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-chatbots-for-better-stakeholder-engagement</link>
		<comments>http://www.tapanray.in/pharma-chatbots-for-better-stakeholder-engagement/#comments</comments>
		<pubDate>Mon, 29 Jul 2019 00:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[answers]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[assistant]]></category>
		<category><![CDATA[automated]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[Chatbots]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[functions]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Merck & Co]]></category>
		<category><![CDATA[Novo Nordisk]]></category>
		<category><![CDATA[outlook]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[Privacy]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[questions]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[satisfaction]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[virtual]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9647</guid>
		<description><![CDATA[The critical value of meaningful interaction and engagement with individual customers &#8211; responding to their specific needs, is fast drawing attention of many businesses, for sustainable performance excellence. The same is happening in the pharma industry, as well. Creative use &#8230; <a href="http://www.tapanray.in/pharma-chatbots-for-better-stakeholder-engagement/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-chatbots-for-better-stakeholder-engagement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Exigency of Cybersecurity in Digitalized Pharma</title>
		<link>http://www.tapanray.in/exigency-of-cybersecurity-in-digitalized-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=exigency-of-cybersecurity-in-digitalized-pharma</link>
		<comments>http://www.tapanray.in/exigency-of-cybersecurity-in-digitalized-pharma/#comments</comments>
		<pubDate>Mon, 08 Oct 2018 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[attack]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[cyber]]></category>
		<category><![CDATA[cybersecurity]]></category>
		<category><![CDATA[digitalized]]></category>
		<category><![CDATA[digitized]]></category>
		<category><![CDATA[employee]]></category>
		<category><![CDATA[espionage]]></category>
		<category><![CDATA[exigency]]></category>
		<category><![CDATA[experienced]]></category>
		<category><![CDATA[hack]]></category>
		<category><![CDATA[hacking]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9204</guid>
		<description><![CDATA[Digitalization – as it unfolds and imbibed by most drug companies, is presumed to herald a whole new ballgame in the Indian pharma business. Equally significant is the quantum benefit that the process will deliver to pharma stakeholders – right &#8230; <a href="http://www.tapanray.in/exigency-of-cybersecurity-in-digitalized-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/exigency-of-cybersecurity-in-digitalized-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Stakeholder Sentiment: Back to Square One?</title>
		<link>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-stakeholder-sentiment-back-to-square-one</link>
		<comments>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/#comments</comments>
		<pubDate>Mon, 28 May 2018 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[George]]></category>
		<category><![CDATA[guru]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Marjin]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[maximizing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[non-profit]]></category>
		<category><![CDATA[one]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sentiment]]></category>
		<category><![CDATA[socializing]]></category>
		<category><![CDATA[square]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8965</guid>
		<description><![CDATA[Is it fair to push out the core purpose of an important process, or rather a mission, unfairly? Whether we like it or not, it happened that way, over a period of time. Way back on December 01, 1950, George W. &#8230; <a href="http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Fraud or Negligence in Drug Quality Standards Not a Fraud on Patients?</title>
		<link>http://www.tapanray.in/is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients</link>
		<comments>http://www.tapanray.in/is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients/#comments</comments>
		<pubDate>Mon, 03 Jun 2013 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Americans]]></category>
		<category><![CDATA[anywhere]]></category>
		<category><![CDATA[Baxter]]></category>
		<category><![CDATA[Boehringer]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[breach]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[charitable]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Claris]]></category>
		<category><![CDATA[contamination]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Dewas]]></category>
		<category><![CDATA[Dr. Reddy's]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[everywhere]]></category>
		<category><![CDATA[facilities]]></category>
		<category><![CDATA[fraud]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Heparin]]></category>
		<category><![CDATA[Hospira]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[IMA]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Ingelheim]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[Jaslok]]></category>
		<category><![CDATA[Jubilant]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Medical Association]]></category>
		<category><![CDATA[Mumbai]]></category>
		<category><![CDATA[OSCS]]></category>
		<category><![CDATA[paonta]]></category>
		<category><![CDATA[pew]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[plants]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Project]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sahib]]></category>
		<category><![CDATA[Schering-Plough]]></category>
		<category><![CDATA[SCS]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[Show]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tolerance]]></category>
		<category><![CDATA[tragedy]]></category>
		<category><![CDATA[trusts]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[Wyeth]]></category>
		<category><![CDATA[zero]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2607</guid>
		<description><![CDATA[As we know, a substance is called a drug when it has scientifically proven and well documented efficacy and safety profile to reduce both mortality and morbidity of patients. Any fraud or negligence in the drug quality standards, for whatever &#8230; <a href="http://www.tapanray.in/is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Could M&amp;As in Pharma create significant stakeholder value?</title>
		<link>http://www.tapanray.in/could-mas-in-pharma-create-significant-stakeholder-value/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=could-mas-in-pharma-create-significant-stakeholder-value</link>
		<comments>http://www.tapanray.in/could-mas-in-pharma-create-significant-stakeholder-value/#comments</comments>
		<pubDate>Mon, 25 Apr 2011 01:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisitions]]></category>
		<category><![CDATA[consolidation]]></category>
		<category><![CDATA[create]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[mergers]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[significant]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[valuation]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=269</guid>
		<description><![CDATA[At the very outset, I pay my homage to the departed soul of our industry colleague respected Amar Lulla, former joint managing director of Cipla, who passed away on Friday, April 22, 2011 after a prolonged battle against cancer. As &#8230; <a href="http://www.tapanray.in/could-mas-in-pharma-create-significant-stakeholder-value/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/could-mas-in-pharma-create-significant-stakeholder-value/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
